Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

219.72 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

23 24 Next >

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 22, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Alnylam Announces New Management Appointments

September 21, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Analysts Put Alnylam On Upside Catalyst Watch Ahead Of Upcoming Data From Lead Program ↗

September 20, 2022

Via Benzinga

Alnylam Receives Approval in Europe for AMVUTTRA® (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy

September 20, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Analyst Ratings for Alnylam Pharmaceuticals ↗

September 09, 2022

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:

Via Benzinga

Alnylam to Host Ninth Annual “RNAi Roundtable” Webcast Series

September 19, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing ↗

September 16, 2022

Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema.

Via Investor's Business Daily

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary ↗

September 15, 2022

Via Benzinga

Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗

September 15, 2022

The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.

Via Investor's Business Daily

Alnylam/Regeneron-Backed NASH Candidate Shows Encouraging Safety Profile In Healthy Volunteers ↗

September 15, 2022

Via Benzinga

Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers

September 15, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Present Additional Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the Heart Failure Society of America Annual Scientific Meeting 2022

September 13, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Pricing of Offering of $900 Million Convertible Senior Notes

September 13, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Why Alnylam Pharmaceuticals Shares Are Falling ↗

September 12, 2022

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares are trading lower by 4.97% to $212.18 Monday morning after the company announced a proposed offering of $900 million convertible

Via Benzinga

Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes

September 12, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Where Alnylam Pharmaceuticals Stands With Analysts ↗

September 09, 2022

Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:

Via Benzinga

Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary ↗

September 08, 2022

Via Benzinga

Alnylam Shares Detailed Patisiran Data From Rare Disease Study ↗

September 08, 2022

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced positive results from the APOLLO-B Phase 3 study of patisiran for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

Via Benzinga

Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

September 08, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentation at Morgan Stanley 20th Annual Global Healthcare Conference

September 06, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Posts Mid-Stage Study Data From Regeneron-Partnered Kidney Disease Drug ↗

August 29, 2022

Via Benzinga

10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others ↗

August 29, 2022

These names are benefitting from M&A, clinical data and promising regulatory actions.

Via Investor's Business Daily

Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy

August 29, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know ↗

August 26, 2022

Moderna Inc (NASDAQ: MRNA) has

Via Benzinga

Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors

August 24, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Present Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the 18th International Symposium on Amyloidosis

August 18, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Will Investors Notice Exciting Sign On Alnylam Pharmaceuticals Chart? ↗

August 17, 2022

If history is any guide, there may be good fortune ahead for shares of Alnylam Pharmaceuticals (NASDAQ:ALNY). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be...

Via Benzinga

If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,000 Today ↗

August 12, 2022

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 15 years by 9.06% on an annualized basis producing an average annual return of 16.5%. Currently, Alnylam...

Via Benzinga

Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion ↗

August 05, 2022

Shares of Pfizer's rumored takeover target have rocketed for two days running.

Via Investor's Business Daily

Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review ↗

August 05, 2022

The Nasdaq and small caps rose while the S&P 500 is hitting resistance.

Via Investor's Business Daily

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.